Author Archives: admin


Teen Thinks She’s Alone During Her Medical Treatment. Then She Notices the Cell Phone at Her Feet – Independent Journal Review

She thought she was alone in the room during her dermatology treatment.But that was before she saw the cell phone.

AsThe Morning Call reports,the 17-year-old girl had been receiving light treatments for a skin condition at Penn Medicine Dermatology in Lower Makefield, Pennsylvania. James Close, a 45-year-old licensed practical nurse, was the technician assigned to help the teen during hertreatments.

On this occasion, the girlundressed and entered the light booth as usual. But as the treatment started, she noticed an iPhone on the floor. Worse, she could see her nude reflection on the screen.

That's when she realized the phone was recording live video and it had been recording her in the nude for about 25 seconds.

Distressed, the teen brought the phone to the clinic's staff, who contacted the police. According to WPVI News, police searched the phone (which was identified as belonging to Close) and found 18videos ofpatients in the light booth.

Bucks County District Attorney's Office

The New York Post reports that the videos depicted the teen and sevenother female patients all of whom were unaware they were being filmed.

Four of the women were totally nude in the video clips and one was undressed from the waist down. Close's voice can be heard in a few of the videos and in one, his face can be seen.

According to the date stamps, Close made the videos between January 18 and February 13. They ranged from 13seconds to three minutes long. There are also threemore videos of the teen girl.

Penn Medicine would not disclose how long Close was an employee or whether he had any previous discipline issues. In a statement to the Post, a Penn Medicine spokeswoman said:

We are appalled at the actions of this former employee and are cooperating fully with the police as they investigate this very disturbing matter.

Now Close has been arrested and charged with more than 45 crimes, including filming a nude child and 36 counts of invasion of privacy. He is currently being held at Bucks County Correctional Facility on $100,000 bail.

Follow this link:
Teen Thinks She's Alone During Her Medical Treatment. Then She Notices the Cell Phone at Her Feet - Independent Journal Review

Kite’s CAR T-Cell Therapy Success – The Scientist


The Scientist
Kite's CAR T-Cell Therapy Success
The Scientist
Last year, both Juno Therapeutics and Kite Pharma announced that a small number of patients had died in their respective CAR T-cell therapy trials. Juno's trial was halted, but Kite's carried on. The Kite study enrolled 77 patients with advanced ...
Gene therapy "seems extraordinary" at fighting blood cancer in study, experts sayCBS News
Terminal cancer patients in complete remission after one gene therapy treatmentTelegraph.co.uk
With Eye On FDA, Kite Says CAR-T For Lymphoma Holds Up After 6 MonthsXconomy
Inquirer.net -Everyday Health (blog) -talkRADIO (press release) -Kite Pharma, Inc. | Investor Relations
all 109 news articles »

Excerpt from:
Kite's CAR T-Cell Therapy Success - The Scientist

Angels Pitcher Put Off Surgery for Stem Cell Treatment – Athletic Business (blog)

Garrett Richards' first thought when he found out about his torn elbow ligament in May was to schedule Tommy John surgery as soon as possible.

It made sense, considering the ligament-replacement procedure has become the standard fix for such injuries. Plus, the Los Angeles Angels ace was familiar with the operating room, having had surgery for a ruptured patellar tendon he suffered on Aug. 20, 2014, toward the end of a breakout season.

Richards knew how to handle the seemingly interminable months of rehab, and he wanted to get the clock started on his return.

But a conversation with Angels head physical therapist Bernard Li convinced Richards to consider other alternatives, and in mid-May he tried a relatively novel treatment in which stem cells taken from bone marrow in his pelvis were injected into the damaged area.

Richards did not pitch again the rest of the year except for a stint in the instructional league, but he has been back on the mound throwing bullpen sessions since the first day of Angels camp and reported no problems.

This weekend, Richards anticipates pitching in a game for the first time since May 1, when his aching elbow forced him from a start after four innings.

"It's nice to know I'll be able to start the season this year and kind of pick up where I left off," Richards said.

A couple of lockers away, fellow starter Andrew Heaney had a different tale to tell.

The promising left-hander also went down with a torn ulnar collateral ligament early in the season, after making one start. Their ailments were the two biggest blows to an Angels rotation that was decimated by injuries, dooming the club to a 74-88 record and a fourth-place finish in the AL West.

Heaney also tried stem cell therapy, two weeks before Richards, both under the supervision of team doctor Steve Yoon. Heaney's ligament didn't heal, though, and after experiencing discomfort throwing after his rehab, he had Tommy John surgery July 1. He has been ruled out for the 2017 season.

"They tell you it's 50-50. It either works, or it doesn't," Heaney said of the stem cell procedure. "Obviously, me and Garrett are pretty much the proof of that rule."

Even with less-favorable odds than reconstructive surgery, which has an 80% success rate for returning to action and 67% for pitching 10 games or more, stem cell therapy is gaining acceptance as an option for pitchers with partial UCL tears. The recovery time is shorter -- three to five months instead of 12 to 18 -- and the treatment less invasive.

There are limitations. Biological approaches based on stem cells or platelet-rich plasma (PRP) won't repair a complete tear of the ligament. The location of the injury and its extent factor into the chances of success. And players whose ligaments don't recover, then have to have surgery, extending their window of time for returning to action.

Even then, the idea of healing without going under the knife is becoming increasingly appealing. New York Yankees ace Masahiro Tanaka treated the small tear in his elbow ligament with PRP and rehabilitation in 2014, sitting out 10 weeks but coming back to pitch in late September.

He's 26-11 with a 3.26 ERA over the last two seasons, raising the profile of PRP -- a procedure in which the player's own blood is used to promote healing of the injury -- as a non-surgical alternative.

Now Richards looms as the test case for stem cell treatment to fix partial UCL tears, which make up about 60-70% of these injuries. If the hard-throwing right-hander can return to his old form -- he was a Cy Young Award candidate before his knee injury in August2014 -- other pitchers in his situation are bound to at least consider the route he took.

"I hope this opens another path for guys," Richards said. "Obviously, if you can prevent being cut on and having surgery, that's the No.1 priority. I hope guys don't just jump right into Tommy John, that they at least explore this option."

Ageless veteran Bartolo Colon was the first pitcher widely known to have undergone stem cell therapy as he sought to recover from elbow and shoulder ailments in 2010. At the time, the ethics of the procedure were questioned, especially because the doctor who performed it, South Florida-based Joseph Purita, acknowledged using human growth hormone in previous treatments, though not in Colon's.

Since then, the use of stem cells has become more mainstream. They are the focus of Yoon's practice.

"As more and more people start to use it, you're getting a better sense for what it can and can't do," Yoon said. "Baseball definitely has opened up to it quite a bit, and as we see some of the successes like with Garrett, we're getting a better understanding that there's a lot of potential here with these types of treatment."

Yoon calls stem cell therapy a "super PRP" because it combines the curative properties of that treatment with more healing agents and says it can be used on tendon tears, muscle tears and strains and even to address degenerative joint disease.

However, much remains unknown about the benefits of stem cells. Lyle Cain, an orthopedist who has performed Tommy John surgeries and stem cell treatments at the Andrews Sports Medicine & Orthopaedic Center in Birmingham, Ala., said most of the research has been anecdotal, not scientific.

"We still don't have a good understanding even four or five years into it exactly what the stem cells do, what their method is," Cain said. "The theory is there's probably a chemical reaction where it releases chemicals in the cell that help the healing process.

"The stem cells aren't necessarily put in there with the thought they're going to become ligament, but there's probably a cellular chemical mechanism that helps the healing response."

And as Heaney discovered, they're not always effective. His tear was located farther down the arm, which reduced his chances of success with stem cell therapy. Richards was a better candidate because his injury, though deemed "high grade," was located within the ligament, like a slit on a rubber band.

But because Heaney was looking at likely missing most or all of 2017 even if he had surgery right away, he decided to try stem cells. The timing of the injury plays a major role in whether pitchers contemplate alternatives to surgery, with the more conservative approach often recommended if it happens early in the season.

Heaney said he doesn't regret taking that route and would have been upset if he had undergone the ligament-replacement operation right away, only to find out he could have returned to action quicker through another means.

"I'm glad it worked for him," he said of Richards. "It would have been really awful if it hadn't worked for either of us. Then we'd both look like idiots."

Their peers are paying attention. In a major league pitching community where about a quarter of its members have had Tommy John surgery, interest in the effectiveness of alternative cures is high.

The Los Angeles Dodgers' Brandon McCarthy was not a candidate because his ligament tore clear off the bone but said he had heard positive reports about stem cell treatment, not so much about PRP.

The Pittsburgh Pirates' Daniel Hudson, a veteran of two Tommy Johns, is encouraged as well.

"It's supposed to help repair the tissue. Before, ligaments just won't repair themselves," Hudson said. "It might keep a lot of guys from going under the knife."

That's Cain's hope. He regularly treats UCL tears on high school, college and minor league players with stem cells or PRP, but realizes there's heightened pressure on major leaguers to return to the field.

If more of them can do it without visiting an operating room, it would represent a major advancement for the players and the industry.

"There will be certain ligaments that are damaged enough that we don't have an answer; they have to reconstruct," Cain says. "But I think overall, if you look 15 years down the road, I suspect we'll be doing a lot more non-surgical treatment than surgical treatment."

Contributing: Gabe Lacques in Bradenton, Fla.

Read More of Today's AB Headlines

Subscribe to Our Daily E-Newsletter

Follow this link:
Angels Pitcher Put Off Surgery for Stem Cell Treatment - Athletic Business (blog)

Stem cell therapy can help treat diabetic heart disease – The … – Economic Times

KARAIKAL: Recent advancements in stem cells research have given hope for successfully treating diabetic heart disease (DHD), renowned New Zealand-based researcher in cardiovascular diseases Dr Rajesh Katare said today.

DHD affected the muscular tissues of the heart leading to complications and it had been demonstrated that resident stem cells of myocardium can be stimulated to repair and replace e degenerated cardiac myocytes resulting in a novel therapeutic effect and ultimately cardiac regeneration, he said.

Katare, Director of Cardiovascular Research Division in the University of Otago, New Zealand, was delivering the keynote address at the continuing medical education programme on "Role of Micro-RNAs and stem cells in cardiac regeneration in diabetic heart disease" at the Karaikal campus of premier health institute JIPMER.

Presenting clinical evidences, Katare said stem cell therapy certainly presented a new hope for successfully treating DHD.

Jawaharlal Institute of Post Graduate Medical Education (JIPMER) Director Dr Subash Chandra Parija pointed out that it was the first such programme on the role of stem cells in cardiac regeneration in the whole of the country.

He said as diabetes was highly prevalent in the country, providing treatment for DHD had become a big challenge. Patients suffering from the condition have to undergo lifelong treatment and medications. "In this backdrop, advancements in stem cell therapy assume significance," he said.

Excerpt from:
Stem cell therapy can help treat diabetic heart disease - The ... - Economic Times

Local man fundraising for Stem Cell Transplant Therapy – Sequim Gazette

Spaghetti dinner fundraiser

Proceeds benefit stem cell transplant for Sean McKeown

When: 4-8 p.m. Saturday, March 4

Where: Sequim Boys & Girls Club, 400 West Fir St., Sequim

Admission: $10 for adults, $6 for children ages 10 and under

For more: Contact Karen McKeown at karenlmckeown@gmail.com or visit https://www.gofundme.com/seans-stem-cell-therapy

Sean McKeown has been living with multiple sclerosis for 17 years.

After trying every medication available to stop the progression of the disease, McKeown finally was approved for stem cell transplant therapy that could significantly help improve his condition.

It has been a 17-year journey for the McKeowns, as Sean and his wife Karen describe it. The two met in a Human Relations class at college in Bellingham and got married six months after Sean was diagnosed with multiple sclerosis.

They now have two young children, Madison, 13, and Dylan, 12, that attend Sequim Middle School.

Sean was born and raised in Port Angeles. The McKeowns have been living in Sequim for five years and work for the family owned business called All Weather Heating and Cooling, Inc. located off Kemp Street in Port Angeles.

Seans parents Tom and Ida McKeown opened the business in the 1980s and later sold it to Seans sister Jeanne Sparks and her business partner Dustin Halverson. Karen currently works as the office manager and Sean also worked at the business until 2009 when he could no longer work.

Sean was first diagnosed with multiple sclerosis in 2000 after experiencing double vision. He is no longer able to take the previous medication he was using for 10 years. Last September, he got a call from the University of Washington that notified him he tested positive for the JC Anti-virus for most people it would be similar to the common cold but when Sean contracts the virus it means half of the multiple sclerosis drugs can cause a second disease called PML or brain cancer.

It was a huge wake up call for us, said Karen.

Multiple sclerosis causes Seans legs to constantly shake and he must walk with the assistance of a cane every day. He also has a lack of energy and at one point was in a wheelchair for several months because he did not have the energy to walk short distances.

The McKeowns said they did a lot of research about stem cell transplant therapy for treating multiple sclerosis and Sean was approved for the procedure after he applied. His approval only lasts for 10 weeks but his insurance does not cover the procedure so the McKeowns must raise $16,000 to cover the cost.

The idea behind the treatment is to take Seans stem cells out of his fat areas, such as the stomach, put the cells through a machine that cleans it and creates new stem cells. Doctors will then inject the cells back into his body where they will attach to blood cells and start the healing process.

For multiple sclerosis, stem cell transplant therapy could help with Seans movement and Karen added that doctors want to put some stem cells in his brain.

Sean explained that the bodys nerve endings are almost like a wire, when talking about the process. He explained his T-cells are attacking the fatty tissue surrounding the nerve endings and when these cells get down to the wire or nerve endings the wires snap and short out, he said.

In theory, those stem cells will re-attach those wires, Karen explained.

StemGenex is the San Diego, Calif.-based facility where the McKeowns will travel to have the procedure done. Karen said the facility has been performing stem cell transplant therapy for nine years to treat other diseases such as Parkinsons. The treatment could be done within three days but if the McKeowns do not raise the money for the procedure within 10 weeks, they will have to reapply.

The McKeowns said they are hoping this procedure will allow Sean to have more energy.

For him, mainly it will be his energy level, Karen said. That would be a huge step in the right direction for him.

Karen explained there were days where Sean could barely walk out to the mailbox and back and would need to rest shortly after.

The McKeowns have been trying to raise money for the procedure through a GoFundMe account and a bank account through First Federal under Benefit for Sean McKeown.

The family also is hosting a fundraiser at the Boys &Girls club in Sequim this Saturday, March 4, where there will be a spaghetti dinner and raffle items. So far the McKeowns have raised an estimated $3,000 and the deadline to reach their goal amount is April 24.

For more information about Sean, you can visit https://www.gofundme.com/seans-stem-cell-therapy.

The spaghetti fundraiser will be held from 4-8 p.m. at the Sequim Boys &Girls Club, 400 West Fir St. in Sequim. Admission is $10 for adults and $6 for children ages 10 and under. Contact Karen McKeown at karenlmckeown@gmail.com.

Visit link:
Local man fundraising for Stem Cell Transplant Therapy - Sequim Gazette

Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with … – Business Wire (press release)

SAN CARLOS, Calif. & BALTIMORE--(BUSINESS WIRE)--Johns Hopkins Medicine, the Maryland Stem Cell Research Fund (MSCRF) and BioCardia, Inc. (OTC:BCDA) today announced that the first patient has been treated in the pivotal Phase III CardiAMP clinical trial of a cell-based therapy for the treatment of ischemic heart failure that develops after a heart attack. The first patient was treated at Johns Hopkins Hospital by a team led by Peter Johnston, MD, a faculty member in the Department of Medicine and Division of Cardiology, and principal investigator of the trial at Johns Hopkins.

The investigational CardiAMP therapy is designed to deliver a high dose of a patients own bone marrow cells directly to the point of cardiac dysfunction, potentially stimulating the bodys natural healing mechanism after a heart attack.

The patient experience with CardiAMP therapy begins with a pre-procedural cell potency screening test. If a patient qualifies for therapy, they are scheduled for a bone marrow aspiration. A point of care cell processing platform is then utilized to concentrate the autologous bone marrow cells, which are subsequently delivered in a minimally-invasive procedure directly to the damaged regions in a patients heart.

This cell-based therapy offers great potential for heart failure patients, said Carl Pepine, MD, professor and former chief of cardiovascular medicine at the University of Florida, Gainesville and national co-principal investigator of the CardiAMP trial. We look forward to validating the impact of the therapy on patients quality of life and functional capacity in this important study.

In addition to Dr. Johnston, the CardiAMP research team at Johns Hopkins includes Gary Gerstenblith, MD, Jeffrey Brinker, MD, Ivan Borrello, MD, Judi Willhide, Katherine Laws, Audrey Dudek, Michele Fisher and John Texter, as well as the nurses and technicians of the Johns Hopkins Cardiovascular Interventional Laboratory.

Funding the clinical trial of this cell therapy, which could be the first cardiac cell therapy approved in the United States, is an important step towards treatments, said Dan Gincel, PhD., executive director of the MSCRF at TEDCO. Through our clinical program, we are advancing cures and improving healthcare in the State of Maryland.

The CardiAMP Heart Failure Trial is a phase III, multi-center, randomized, double-blinded, sham-controlled study of up to 260 patients at up to 40 centers nationwide, which includes an optional 10-patient roll-in cohort. The primary endpoint for the trial is a significant improvement in Six Minute Walk distance at 12 months post-treatment. Study subjects must be diagnosed with New York Heart Association (NYHA) Class II or III heart failure as a result of a previous heart attack. The national co-principal investigators are Dr. Pepine and Amish Raval, MD, of the University of Wisconsin.

For information about eligibility or enrollment in the trial, please visit http://www.clinicaltrials.gov or ask your cardiologist.

About BioCardia BioCardia, Inc., headquartered in San Carlos, CA, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the companys biotherapeutic product candidates in clinical development. For more information, visit http://www.BioCardia.com.

About Johns Hopkins Medicine Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is one of the leading health care systems in the United States. Johns Hopkins Medicine unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. For more information, visit http://www.hopkinsmedicine.org.

About Maryland Stem Cell Research Fund The Maryland Stem Cell Research Act of 2006was established by the Governor and the Maryland General Assembly during the 2006 legislative session and created the Maryland Stem Cell Research Fund. This fund is continued through an appropriation in the Governor's annual budget. The purpose of the Fund is to promote state-funded stem cell research and cures through grants and loans to public and private entities in the State. For more information, visit http://www.MSCRF.org.

Forward Looking Statements This press release contains forward-looking statements as that term is defined under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, among other things, references to the enrollment of our Phase 3 trial, commercialization and efficacy of our products and therapies, the product development timelines of our competitors. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardias business and product development plans, competition in the industry in which BioCardia operates and overall market conditions, and whether the combined funds will support BioCardias operations and enable BioCardia to advance its pivotal Phase 3 CardiAMP cell therapy program. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

See the rest here:
Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with ... - Business Wire (press release)

Findings reveal effect of embryonic neural stem cell development on later nerve regeneration capacity – Medical Xpress

March 1, 2017 Neural progenitor cells (green) in the lateral ganglionic eminence (LGE), the region in the developing brain that produces the majority of adult neural stem cells. Credit: Sven Falk

Neurodegenerative diseases such as Alzheimer's or Parkinson's, but also strokes or other types of traumatic brain damage, result in the death of nerve cells in the brain. Since the mammalian brain is capable of replacing nerve cells only in certain restricted regions, such nerve-cell loss is in most cases permanent. Similarly, the capacity to form new nerve cells in the mature brain is limited to specific areas. The cells responsible for neurogenesis in the mature brain are called adult neural stem cells, but little is known about their developmental origins. Now an international research collaboration led by Magdalena Gtz, Professor of Physiological Genomics at LMU's Biomedical Center and Director of the Institute for Stem Cell Research at the Helmholtz Zentrum Munich, has demonstrated that the mode of division of stem cells has a profound influence on the numbers of adult neural stem cells formed during embryonic development.

The new findings appear in the journal Neuron.

Neural cells develop from progenitors called neural stem cells, which are produced in large numbers during embryonic development. However, in the mature mammalian brain, very few of these progenitors survive as so-called adult neural stem cells capable of generating new nerve cells. In order to determine what enables these cells to retain their stem-cell character into adulthood, Gtz and her colleagues took a closer look at neural stem cells in the developing mouse embryo called radial glia cells (RGCs). RGCs form long processes that span the apicobasal axis of the neuroepithelium and their nuclei come to lie close to the apical surface which faces a fluid-filled cavity known as the ventricle. When RGCs divide, some of the daughter cells again are RGCs, i.e. the RGC self-renews. These cells that retain the self-renewing capacity, a characteristic of stem cells, are the source of the adult neural stem cells found in a specific region of the developing brain called the lateral ganglionic eminence, which forms the lateral wall of the ventricle in the adult brain. The nerve cells derived from the adult neural stem cells subsequently migrate into the olfactory bulb, one of the regions in which new nerve cells are integrated in the mature brain.

"We have now shown that the orientation of the plane of division of embryonic progenitor cells has a major impact on the production of adult neural stem cells," Gtz says. The plane of cleavage during cell division determines which parts of the cytoplasm are inherited by the two daughter cells. Most of the RGCs in the lateral ganglionic eminence were found to divide along a plane that is approximately vertical (at an angle of 60-90) to the apical cell surface. However, when the researchers genetically randomized the orientation of the cleavage plane such that the frequency of oblique or horizontal divisions was increased the number of adult neural stem cells generated was significantly reduced. Hence the orientation of the cleavage plane of RGCs is a crucial factor that affects the number of adult stem cells. However, timing also plays a crucial role. Adult neural stem cells are produced only during a specific, temporally and regionally restricted phase in embryonic development. Genetic randomization of the cleavage plane progenitor cells in the post-natal mouse brain proved to have no effect on the number of adult stem cells.

The total number of adult neural stem cells produced is a crucial determinant of the brain's capacity for repair and regeneration, because each of these cells can generate only a limited number of new nerve cells. "With a better understanding of how the formation of adult neural stem cells is regulated, we could look for ways of ensuring that other embryonic neural stem cells maintain this capacity, and perhaps even persuade other cell types to do so. Our new results represent an important step toward this goal," says Sven Falk, first author of the new study. The researchers hope that their findings will open up new approaches to the therapy of neurodegenerative diseases.

Explore further: Specific roles of adult neural stem cells may be determined before birth

More information: Sven Falk et al. Time-Specific Effects of Spindle Positioning on Embryonic Progenitor Pool Composition and Adult Neural Stem Cell Seeding, Neuron (2017). DOI: 10.1016/j.neuron.2017.02.009

Adult neural stem cells, which are commonly thought of as having the ability to develop into many type of brain cells, are in reality pre-programmed before birth to make very specific types of neurons, at least in mice, according ...

Stem cells in the brain can produce neurons and are consequently seen as a hope for treatment. A team of researchers from the Helmholtz Zentrum Mnchen and Ludwig-Maximilians-Universitt Mnchen (LMU) has now discovered ...

Prof. Fiona Doetsch's research team at the Biozentrum, University of Basel, has discovered that the choroid plexus, a largely ignored structure in the brain that produces the cerebrospinal fluid, is an important regulator ...

Blood vessels play a vital role in stem cell reproduction, enabling the brain to grow and develop in the womb, reveals new UCL research in mice.

(Medical Xpress)A team of researchers with the Allen Institute for Brain Science led by Christof Koch gave a presentation recently at the Brain Research through Advancing Innovative Neurotechnologies meeting outlining ...

How does consciousness arise? Researchers suspect that the answer to this question lies in the connections between neurons. Unfortunately, however, little is known about the wiring of the brain. This is due also to a problem ...

Happy memories spring to mind much faster than sad, scary or peaceful ones. Moreover, if you listen to happy or peaceful music, you recall positive memories, whereas if you listen to emotionally scary or sad music, you recall ...

Scientists at the Institute for Infectious Diseases, University of Bern have developed an in vitro stem cell-based bioassay grown on multi-electrode arrays capable of detecting the biological activity of Clostridium botulinum ...

What happens in your brain when you tell a joke? Well, that appears to depend on whether you do that for a living.

In recent years, reams of research papers have shed light on the health benefits of probiotics, the "good bacteria" found in fermented foods and dietary supplements. Now a first-of-its kind study by University of Colorado ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More:
Findings reveal effect of embryonic neural stem cell development on later nerve regeneration capacity - Medical Xpress

Stem cell treatment changed the life of one guest at Trump’s speech – CNN

She credits an experimental stem cell treatment with giving her new hope for her health and her future -- a newfound hope that also caught attention of Republican Rep. Pete Olson.

"She is the face of the 21st Century Cures Act because of what she's gone through in her life," he said Tuesday.

"It became pretty clear to me that ... I (have) got to tell her story," he said. "That's why she's here: She's awesome."

Immediately after the House vote, Hughes said, Olson called her at home to invite her to be his guest of honor.

"I still cannot believe I will be in the same room as our President and lawmakers," she said before attending Trump's speech.

It took Crowley's father, John, to launch the New Jersey biotechnology company Amicus Therapeutics to identify a drug treatment that would save her life, Trump said.

"If we slash the restraints, not just at the FDA but across our Government, then we will be blessed with far more miracles like Megan," he said. "In fact, our children will grow up in a Nation of miracles."

Hughes spent most of her adolescence hospitalized, as she became so sick that she could barely walk and suffered immense pain. Her body was evaluated, treated and studied at the National Institutes of Health in collaboration with her doctors from the University of Texas Health Science Center at Houston.

Yet relief came in 2014, when Hughes received a high-dose adult stem cell treatment that was not approved in the United States.

For the procedure, Hughes had her own healthy stem cells cultured at the FDA-registered biotechnology company Celltex Therapeutics in Houston. Then she traveled to Cancun, Mexico, to have the cells infused back into her body.

Each infusion involved about 200 million stem cells, and Hughes received some 22 infusions over almost two years. The cells could help normalize her immune system, which was overactive due to her autoimmune disease.

Before the stem cell therapy, Hughes said, she was taking 23 medications a day. Now, she is on eight medications at lower doses.

"If not for the help of high-dose autologous mesenchymal stem cell therapy, I would not be here today," Hughes said at the hearing.

"I was running out of time, but I was willing to put my life at risk to get on an airplane. My quality of life had become so dismal, even one small improvement from my own stem cells would have been enough for me," she said in her speech. "What happened in the days, weeks and years following my first infusion has changed my outlook. It's hard to believe, in my sick body, I had a wealth of healthy adult stem cells with the ability to so significantly improve my quality of life."

"My hope is that our new President will spend time looking at how to help all Americans have access to new therapies like the one I had," she said.

Excerpt from:
Stem cell treatment changed the life of one guest at Trump's speech - CNN

Bones made to order at University of Rochester, thanks to 3-D printers – Rochester Democrat and Chronicle

Scientists at URMC are researching how to use 3-D printing to create bone replacement. Jamie Germano

University of Rochester Medical Center Scientists Hani Awad, left, and Edward Schwarz explain how they are leading the way in using 3-D printing and stem cells to create bone replacements for patients.(Photo: Jamie Germano/@jgermano1/Staff Photographer)Buy Photo

Imagine getting a made-to-order bone implanted in your body that's composed of your own cells.

Scientists at the University of Rochester Medical Center have been developing a procedure to use3-D printing and stem cells fromthe patient to createbones made of regenerated tissue.

Thismulti-step procedure still has a ways to go before it is tested on humans and can become part of the services provided by URMC's Center for Musculoskeletal Research.Butit's the latest example of how 3-D printing, which isincreasingly finding its place in manufacturing, is leaving its mark in medicine.

It is changing the way we do a lot of things, saidHani Awad, who is associate director of the center and professor of biomedical engineering with aspecialty in tissue engineering.

Biomedical research, as it is being done in this initiative, is an important component of the medical center's identity.

"Part of our mission is that we want to do research that is impactful," said Stephen Dewhurst, vice dean for research at the medical center.

A 3-D replica of a spinal deformity in a child that gives surgeons a hands-on look at a problem before surgery. The replica is made with a 3-D printer at the University of Rochester Medical Center.(Photo: Jamie Germano/@jgermano1/Staff P)

UR is already using 3-D printing to create replicas of human organs to practice on before conducting difficult surgical procedures.

The Center for Musculoskeletal Research is trying to gobeyond this use of3-D printing.

Simulated surgery makes headway at UR Medical Center

Edward Schwarz, director of the center, andAwadare heading up an initiative that not only makes replicas of bones for doctors to better understand and show patients the problems they face, butis alsousing 3-D printing to create the framework for regenerating bone tissue.

Currently, a person with a badly damaged limb that cannot be healed by surgical means faces amputation, followed bythe fitting of an artificial limb.

Bones from cadavers arealso sometimes used as replacement limbs, but there is a high failure rate withcadaver limbs over time. That's because cadaver bonesare not living tissue and thus cannot repair themselves when the limb suffers minor fractures, as they often do.

Bone regeneration offers the prospect of a new alternative.

Thesurgically implanted replica serves as a framework to regenerate bone tissue.

"A big part of the problem is figuring out how to grow a big piece of bone,"said Awad.

With the technology developed, a3-D replicais created by taking a CT scan of the patient's bone. What's recorded by the scan is thenconverted by a computer into a digital modelthat programsthe 3-D printer.

If a leg is too badly damaged tomake a replica, a CTscan can be taken of the patient's other leg. And with the use of computer technology, any needed modification can be made. ACT scan of a left leg could be made to look like it isa right leg in the 3-D printout.

RELATED STORIES:

(2016 video)Simulated surgery at UR Medical Center

(2015) UR doctors use 3-D printing to save woman's life

(2015)Students summer job: Making prosthetic hands at RIT

During a recent demonstration, thestainless steel platform of the 3-D printer,which moves up and down, wasreplenished with a supply of powdered calcium phosphate a materialsimilar to bone.

The printer's inkjets wereprogrammed by computer to spray a binding solution of phosphoric acid in a patternthat formed a thighbone.

Over the course of an hour or so, the 3-D printer creating one thin layer on top of another builtthe artificial human boneabout 1 inch thick and 6inches long.

But that's not where this bone replacement procedure ends.

The next step and one not yet tried on humans is regeneration of tissue using stem cells wrapped around the replacementbone.

Schwarz and Awad have beentesting bone regeneration on mice, without any indicationof rejection and with signs of bone regeneration.

And they are beginning to test regeneration on mini-pigs.

The 3-D replica bones arecoated with sheets ofstem cells, whichregenerate bone tissue. Eventually, the 3-D part of the replacement bones made of calcium phosphate isexpected to be absorbed by new bone tissue.

Awad estimates that this tissue regeneration technology couldbe triedon humans in three to five years.

Research at the University of Rochester uses 3-D printing to create bone replacements. Jamie Germano

UR is among a handful of universitiesdoing research that combines 3-D technologyand tissue regeneration.

"The exact horizon is unclear, but we are certainlyrunning full-speed ahead," said Dr. Paul Rubery, chairman of the Department of Orthopaedics at the UR Medical Center.

3-D printing, Rubery noted, makes possible the reproduction of intricate shapes, including those in the human body.

"What is the science one might say what is the magic that will make a person's body take on a new part and make it a living part?" said Rubery about the possibility of bone regeneration using stem cells and 3-D technology.

The Medical Center is well positioned to figure this out.

"We havea long tradition of understanding the molecular processes that lead to healing and repair of the skeleton," said Rubery.

The Musculoskeletal Center, which is inRubery'sdepartment, last fiscal year received the second highest amount of funding for such centers fromthe National Institutes of Health roughly $10 million. About65 researchers and technicians are on staff.

The other half of the equation is the Medical Centers Upstate Stem Cell cGMP Facility, where stemcells are grown in accordance with strict Food and Drug Administration regulations.

Located in the Medical Center's Ernest J. Del Monte Neuromedicine Institute, the cGMP was established in 2012, with the help of a $3.5 million grant from the Empire State Stem Cell Board.

In bone regeneration, the stem cells are usually taken by syringe at the hip, where such cells are plentiful, and then grown in petri dishes atthecGMP Facility.

Schwarz, who is a professor of orthopaedics, said what's mostneeded before the procedure can beused on humans is work on how the stem cells are transferred from the cGMP facility to the 3-D replicas.

"Youbasically have to demonstrate that you can harvest the cells, grow the cells andre-implant the cells in a safe and effective manner," said Schwarz.

Currently, the alternative to an artificial leg is one from a cadaver, but that is done only in limited situations.

"If the bone is not alive, it eventually becomes structurally weakened," said Dewhurst.

Bone grafts are also done, buthere, too,the graftcomesfrom cadavers in thevast majority of cases, said Awad.

Regenerating bone tissue would provide a different dynamic creating live bone tissue that replenishes itself.

Rejection is not expected to be an issue because the stem cellswould come from the patient.

Unlike other cells, stem cells have the capability to divide indefinitely, so they can grow new bone tissue.

Awad and Schwarz are among the authors of studies in scientific journals that show the effectiveness of stem cells in healing damaged bones in mice.

In a laboratory at the Musculoskeletal Center is a tabletop full of replicas of human bones and bone structures made by the 3-D printer in the room.

The replica of the spine is that of a childwho suffered from a severe curvature.

Having such a model enabled a doctor to figure out what kind of steps could be taken to address the problem.

The 3-D skull on the table is a replica of a human skulland provides a way researchers can study howinjuries can be treated.

A hole was made in the cheekbone to resemble a bullet wound. Another replicawas missing part of a jaw.

Inboth cases, the goalis to have stem cells regenerate bone tissue.

The body can naturally healitself in the normal course of injuries, but can't do so when the bone is damaged beyond repair.

Implanting a 3-D bone coated withhuman stem cells would offer an alternative to existing choices.

"It is really going to be part of UR Medicine and its health care system," said Schwarz.

JGOODMAN@Gannett.com

Read or Share this story: http://on.rocne.ws/2mbSju6

Read the rest here:
Bones made to order at University of Rochester, thanks to 3-D printers - Rochester Democrat and Chronicle